<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Layout Recreation</title>
    
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;600;700&display=swap&quot; rel="font" />
    <link  rel="stylesheet" href="main.css">

</head>
<body>

  <div class="header">s
    CORRESPONDENCE
    <span class="label">| Nov 13, 2024 | <span class="free">FREE</span></span>
  </div>

  <div class="image">
   <img src="./images/chart.png" alt="">
    
  </div>

  <h1>Activity of Research-Grade Pemivibart against SARS-CoV-2 Sublineages</h1>
  <h2>Q. Wang and Others</h2>

  <p class="article-body">
    SARS-CoV-2 continues to evolve under immunologic pressure. A
    synthesized version of pemivibart, an antiâ€“SARS-CoV-2 monoclonal
    antibody with recent emergency-use authorization, showed mixed
    activity against emerging variants.
  </p>

  <p class="correction">
  <strong>Correction</strong>
  <a href="#">Pemivibart Activity against Recent SARS-CoV-2 JN.1
    Sublineages</a>
</p>

</body>
</html>